Rising Medical Device Recalls Put Supply Chain Resilience and Patient Care at Risk

Medical device recalls are not slowing down. FDA has acknowledged that it does not have the capacity to manage the current volume, creating a serious challenge for hospitals already absorbing cost pressure, tariff uncertainty, and a tight labor market.

Recalls are going to happen. They are unavoidable. But there are good recalls and bad recalls. It is all about how they are handled by the reporting firm and by the authorities that oversee them—namely, FDA. Lack of capacity at FDA to perform this role is unacceptable, both in terms of managing patient risk and in terms of healthcare supply chain resilience and economics.

High-Severity Recalls Are a Supply Chain Issue

A number of recent high-severity device recalls illustrate the stakes. These include Boston Scientific’s pacemaker recall after reported deaths and injuries, Abbott’s glucose sensor recall after reported deaths and hundreds of injuries, J&J MedTech’s neuro device recall, Medtronic’s heart vent catheter recall and Abiomed’s heart pump recalls.

These are not minor labeling issues or administrative corrections. They are serious recalls involving products used in critical care settings, in some cases with patient deaths associated with the underlying device issues.

From a healthcare supply chain perspective, recalls mean supply chain disruptions and cost increases. Hospitals may have to pull products from inventory, locate alternative suppliers, adjust clinical workflows, retrain staff, and manage the financial consequences of moving outside existing contracts. A device recall can quickly become a patient care event.

The Medline Example

Several recent recalls have also been associated with Medline’s catheter reprocessing business. Some of these recalls have been classified as Class I recalls, the most serious level of recall, indicating a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death.

One recall involving intracardiac echocardiography catheters described the issue as devices containing small residual particulates. Use of devices with residual particulates on patient-contacting surfaces may create a risk of inflammatory response or systemic infection. If particulate dislodges during use and comes into contact with circulating blood or the heart, it could produce a granulomatous reaction or thrombus formation, potentially leading to cerebral or pulmonary embolism, or deep vein thrombosis.

It is important to note that reprocessing is a successful practice because clinicians, service line managers, and hospital leadership believe in the safety and functionality of reprocessed products. In general, single-use device reprocessing is a safe, FDA-regulated practice, and there is no reason to believe that the recent large number of Medline recalls reflects a poor safety record of the reprocessing industry in general.

When Timing Matters

The Medline recall timeline shows what FDA delays can mean in practice. On July 14, 2025, Medline sent affected customers an “Urgent Medical Device Recall” communication. On August 13, 2025, Medline sent an updated communication to previously notified and additional customers containing additional affected product.

In a Dec. 22, 2025 letter to affected customers, Medline stated that specific lots of reprocessed electrophysiology and ultrasound catheters may contain small residual particulates. FDA ultimately reported the issue on March 5, 2026. On June 18, 2026, FDA published another expansion of the recall, which covered nine different device families and 134 lot numbers.

Medline did everything it could to inform its customers, and, to date, Medline has not reported any serious injuries or deaths related to this issue. That is important context. The problem is not that a manufacturer notified customers and expanded a recall as more information became available. The delay in FDA’s reporting is the problem.

At the same time, the large number of high-severity recalls from medtech companies is another problem. Are medtech companies sufficiently committed to ensuring a constant supply of high-quality medical devices? Packaging glitches happen. Mislabeling happens. But these are high-severity recalls, and in some cases patient deaths have been associated with the recalled products. 

Designed for Cost, Not Disruption

Most hospital supply chains have been designed to minimize costs, not to handle supply chain disruptions. Single-vendor contracts are a good example. These arrangements can reduce variation and help control expenses under normal conditions, but they can also leave hospitals exposed when a critical product is recalled.

When a recall occurs, the hospital often has to scramble to find alternative suppliers at a higher cost. That process can involve emergency sourcing, substitute product evaluations, physician preference discussions, contracting changes, and operational workarounds. None of this is easy in a healthcare environment already under financial pressure.

Medical supply chain costs are expected to rise in 2026. Reimbursement is not increasing at the same rate. Ultimately, the large number of high-severity recalls will increase the already intense pressure on the hospital bottom line and affect the hospital’s ability to provide timely care to its patients.

Recall Readiness Is Patient Care

Recall readiness is part of patient safety, financial stewardship, and supply chain resilience. It requires diligence on the behalf of hospitals, manufacturers, and FDA itself. 

Hospitals need better visibility into lot-level inventory, stronger recall playbooks for clinically critical categories, pre-vetted substitute products, and clearer communication channels across departments. Manufacturers need to communicate quickly, plainly, and repeatedly as recall scopes change. And FDA needs the capacity to provide timely oversight and public reporting.

There will always be recalls. The difference between good recalls and bad recalls is whether the healthcare system can contain the risk before it becomes a larger failure of trust, access, and cost control. Medical device recalls are not just regulatory events. They are supply chain events and, increasingly, patient care events.